Publications in collaboration with researchers from Albany Medical Center Hospital (2)

2016

  1. Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: Results of two Phase 2 randomised controlled trials

    Clinical and Experimental Rheumatology, Vol. 34, Núm. 3, pp. 430-442

2012

  1. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.

    Arthritis and rheumatism, Vol. 64, Núm. 4, pp. 970-981